Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

C.E.M. Griffiths,Maurizio Fava,Andrew H. Miller,James A. Russell,Susan Ball,W. Xu,Nayan Acharya,Mark Hyman Rapaport

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

2017

C.E.M. Griffiths
Maurizio Fava
Andrew H. Miller
James A. Russell
Susan Ball
W. Xu
Nayan Acharya
Mark Hyman Rapaport

Background: Depression is a common comorbidity in psoriasis, and both conditions are associated with systemic inflammation. The efficacy of ixekizumab, a high-aff

Keywords:

Psoriasis
Comorbidity
Ixekizumab
Systemic inflammation
Medicine
Diabetes mellitus
Physical therapy
Clinical psychology
Severity of illness
Etanercept
Inflammation
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations